A retrospective study to determine usefulness of 177Lu-DOTA-0-Tyr3-Octreotate (DOTATATE) healthy organs (spleen, kidneys, bone marrow) standard uptake value for prediction of subacute hematological toxicity
Latest Information Update: 23 Jan 2023
At a glance
- Drugs Lutetium-(177Lu)-oxodotreotide (Primary)
- Indications Neuroendocrine tumours
- Focus Adverse reactions
Most Recent Events
- 23 Jan 2023 New trial record
- 09 Dec 2022 Results published in the Medicine